ORKA Stock: Insider Activity, Filings & Research

Oruka Therapeutics, Inc. (ORKA) — Drillr’s hub for ORKA insider activity, SEC filings, earnings signals and AI research. Over the trailing 3 months, ORKA insiders filed 0 open-market buys and 27 sales (SEC Form 4).

Sentiment

0/100

Buys (3m)

Sells (3m)

Net (3m)

-$8.5M

Insider trades by month Buys Sells

Dec

Jan

Feb

Mar

Apr

May

Context3-month price +63.5%Institutions accumulating (13F)

Date	Insider	Type	Shares	Price
May 22, 2026	Dambkowski Carldirector	Sell	13,235	$59.97
May 22, 2026	Dambkowski Carldirector	Option	38,689	$6.84
May 22, 2026	Dambkowski Carldirector	Option	11,904	$7.80
May 22, 2026	Dambkowski Carldirector	Option	11,667	$11.77
May 22, 2026	Dambkowski Carldirector	Sell	38,318	$58.43
May 22, 2026	Dambkowski Carldirector	Sell	53,447	$59.10
May 18, 2026	Agarwal Arjunofficer: Senior Vice President, Finance	Option	5,833	$34.39
May 18, 2026	Agarwal Arjunofficer: Senior Vice President, Finance	Option	2,000	$12.50
May 18, 2026	Agarwal Arjunofficer: Senior Vice President, Finance	Sell	700	$61.16
May 18, 2026	Agarwal Arjunofficer: Senior Vice President, Finance	Sell	800	$60.34
May 18, 2026	Agarwal Arjunofficer: Senior Vice President, Finance	Sell	4,600	$59.19
May 18, 2026	Agarwal Arjunofficer: Senior Vice President, Finance	Sell	4,190	$58.34
May 15, 2026	Goncalves Joanaofficer: Chief Medical Officer	Option	3,500	$6.84
May 15, 2026	Goncalves Joanaofficer: Chief Medical Officer	Sell	4,800	$61.56
May 15, 2026	Goncalves Joanaofficer: Chief Medical Officer	Sell	2,100	$62.42

Source: ORKA SEC Form 4 filings, latest May 22, 2026. For informational purposes only — not investment advice.

Overview

Oruka Therapeutics, Inc. (NASDAQ:ORKA) is a clinical-stage biotechnology company founded to develop innovative monoclonal antibody treatments for inflammatory and immunological diseases. Based in Menlo Park, California, the company focuses specifically on developing therapies for psoriasis and other immune-mediated inflammatory conditions. As a pre-revenue biotech firm, Oruka is currently advancing its pipeline of experimental drugs through clinical trials, with its lead candidates being ORKA-001 and ORKA-002.

Business

Oruka operates in the biotechnology sector, specifically focusing on developing monoclonal antibody therapeutics for inflammatory and immunological (I&I) diseases. Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance, or mimic the immune system's attack on cells. These sophisticated biological drugs are designed to target specific proteins or cells involved in disease processes. The company's primary focus is on psoriasis (PsO), a chronic autoimmune skin condition that affects millions of people worldwide. Psoriasis occurs when the immune system mistakenly attacks healthy skin cells, causing them to multiply rapidly and form thick, scaly patches on the skin's surface. Current treatments range from topical creams to systemic immunosuppressive drugs, but many patients still struggle with inadequate symptom control or significant side effects. Oruka's pipeline centers around two main drug candidates: ORKA-001 and ORKA-002. While specific details about these compounds' mechanisms of action are limited in the available financial data, both are being developed as monoclonal antibody treatments targeting different aspects of the inflammatory cascade involved in psoriasis and potentially other immune-mediated conditions. As a single-focus company, essentially 100% of Oruka's research and development efforts are concentrated on these I&I therapeutic programs.

Revenue model

As a pre-revenue clinical-stage biotechnology company, Oruka currently generates no commercial revenue. The company's business model is built around the drug development and licensing paradigm common in biotech, where the ultimate goal is to successfully develop drugs through clinical trials and either commercialize them independently or partner with larger pharmaceutical companies through licensing deals. The company's current funding comes from equity financing, as evidenced by its substantial cash reserves of approximately $84 million as of Q1 2025. Biotech companies typically raise capital through public offerings, private placements, or strategic partnerships to fund their expensive clinical trial programs, which can cost tens to hundreds of millions of dollars per drug candidate. Future revenue potential depends on several critical factors. Regulatory approval success is paramount - drugs must pass through Phase I, II, and III clinical trials before gaining FDA approval. Market competition significantly impacts potential returns, as the psoriasis treatment market already includes established biologics from major pharmaceutical companies like AbbVie (Humira, Skyrizi) and Johnson & Johnson (Stelara). Clinical differentiation will be crucial - Oruka's drugs must demonstrate superior efficacy, safety, or convenience compared to existing treatments. Additionally, manufacturing costs and pricing pressure from payers and biosimilar competition could impact future margins, while patent protection duration will determine the exclusivity period for commercialization.

Competitive moat

Oruka's competitive moat is currently limited and largely theoretical, as is typical for early-stage biotech companies. The company's primary potential moat lies in intellectual property protection around its specific monoclonal antibody formulations and any novel mechanisms of action they may possess. However, without detailed information about the unique properties of ORKA-001 and ORKA-002, it's difficult to assess how defensible these positions are. The psoriasis treatment market is highly competitive, dominated by established pharmaceutical giants with deep pockets and extensive commercial infrastructure. Companies like AbbVie, Novartis, and Johnson & Johnson have multiple approved biologics and decades of experience in immunology. Regulatory barriers provide some temporary protection, as the lengthy and expensive clinical trial process creates natural barriers to entry, but this protection evaporates once competitors develop similar or superior treatments. Potential disruption could come from multiple directions: larger pharmaceutical companies with superior resources developing next-generation treatments, breakthrough therapies using novel approaches like gene therapy or advanced cell therapy, or even existing competitors expanding their indications or improving their formulations. The company's small size and limited resources make it particularly vulnerable to being outpaced by better-funded competitors. Without established commercial relationships, manufacturing capabilities, or proven clinical differentiation, Oruka's moat remains largely dependent on the success and uniqueness of its current pipeline assets.

Risks & safety

Oruka presents a moderate to high-risk financial profile typical of clinical-stage biotech companies, with significant cash reserves but substantial ongoing losses. • Cash position: $83.6 million in cash and short-term investments as of Q1 2025, down from $410.9 million in Q3 2024, indicating significant capital deployment • Burn rate: Quarterly cash burn of approximately $21 million based on Q1 2025 operating cash flow, suggesting roughly 4 quarters of runway at current spending levels • Debt level: Minimal debt with debt-to-equity ratio of only 0.26%, indicating strong balance sheet structure • Solvency: Current ratio of 30.0x demonstrates excellent short-term liquidity, though this is primarily due to cash reserves rather than operational strength • Valuation metrics: Trading at 1.17x book value and negative earnings multiples due to development-stage losses • Other considerations: Zero revenue generation creates binary risk profile dependent entirely on clinical trial outcomes; substantial net losses of $84 million in 2024 reflect typical R&D-intensive biotech spending patterns

Recent development

Based on the available financial data, Oruka appears to be in an active clinical development phase, as evidenced by its substantial and consistent quarterly cash burn rates averaging $20-35 million per quarter. The significant reduction in cash reserves from over $410 million in Q3 2024 to $84 million in Q1 2025 suggests the company has been aggressively funding clinical trials and advancing its pipeline programs. The company's research and development expenditures have remained consistently high, with quarterly net losses ranging from $21 million to $29 million, indicating sustained investment in advancing ORKA-001 and ORKA-002 through clinical trials. This spending pattern is typical of biotech companies moving their lead candidates through Phase II or Phase III trials, which require larger patient populations and more extensive clinical infrastructure. Without access to detailed earnings call transcripts, specific strategic developments and pipeline milestones cannot be precisely identified. However, the financial trajectory suggests Oruka has been prioritizing clinical advancement over business development activities, focusing resources on generating clinical data rather than pursuing immediate partnership opportunities. The company's substantial cash deployment indicates it is likely conducting pivotal trials that could serve as the basis for regulatory submissions or partnership discussions.

ORKA company profile · for informational purposes only — not investment advice.

Track ORKA with Drillr

SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.

Try Drillr for free